Stock Analysis
Torrent Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations
Torrent Pharmaceuticals (NSE:TORNTPHARM) Full Year 2024 Results
Key Financial Results
- Revenue: ₹107.3b (up 12% from FY 2023).
- Net income: ₹16.6b (up 33% from FY 2023).
- Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: ₹48.94 (up from ₹36.79 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Torrent Pharmaceuticals EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.8%.
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are down 2.1% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Torrent Pharmaceuticals that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether Torrent Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether Torrent Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:TORNTPHARM
Torrent Pharmaceuticals
Engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally.
Outstanding track record with high growth potential and pays a dividend.